Metadate ER en es it fr

Metadate ER Brand names, Metadate ER Analogs

Metadate ER Brand Names Mixture

  • No information avaliable

Metadate ER Chemical_Formula


Metadate ER RX_link

Metadate ER fda sheet

Metadate_ER FDA

Metadate ER msds (material safety sheet)

Metadate_ER MSDS

Metadate ER Synthesis Reference

M. Hartmann, L. Panizzon, U.S. Pat. 2,507,631 (1950)

Metadate ER Molecular Weight

233.306 g/mol

Metadate ER Melting Point


Metadate ER H2O Solubility


Metadate ER State


Metadate ER LogP


Metadate ER Dosage Forms

Tablets; Tablets (sustained release)

Metadate ER Indication

For use as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate-to-severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity.

Metadate ER Pharmacology

Methylphenidate is a central nervous system stimulant used most commonly in the treatment of attention-deficit disorders in children and for narcolepsy. Its mechanisms appear to be similar to those of dextroamphetamine.

Metadate ER Absorption

Readily absorbed in a biphasic manner. It reaches peak absorption at approximately two hours for the first phase and five hours for the second phase. Bioavailability is low (approximately 30%)

Metadate ER side effects and Toxicity

Symptoms of overdose include vomiting, agitation, tremors, hyperreflexia, muscle twitching, convulsions (may be followed by coma), euphoria, confusion, hallucinations, delirium, sweating, flushing, headache, hyperpyrexia, tachycardia, palpitations, cardiac arrhythmias, hypertension, mydriasis, and dryness of mucous membranes. LD50=190mg/kg (orally in mice)

Metadate ER Patient Information

Metadate ER Organisms Affected

Humans and other mammals